Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,270 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pathway Clear all
Not yet recruiting Phase 1Phase 2 Interventional

Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations

NCT07670156
View directory record Official record
Conditions
JAK1 GOF, STAT1 GOF, STAT3 GOF, STAT5B GOF, STAT6 GOF
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
Lisa Satter
Other
Eligibility
12 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
St Louis, Missouri • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 30, 2026, 9:21 PM EDT
Recruiting Phase 2 Interventional

Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT): Open Label

NCT07689773
View directory record Official record
Conditions
Olfactory Impairment
Interventions
Trigeminal Nerve Stimulation-enhanced Smell Training
Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 9:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pathways for Parents After Incarceration Feasibility Study

NCT04525703
View directory record Official record
Conditions
Parenting, Development, Child, Behavior
Interventions
Pathways for Parents after Incarceration
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 30, 2026, 9:21 PM EDT
Completed Phase 3 Interventional Results available

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

NCT04701203
View directory record Official record
Conditions
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
TransCon PTH, Placebo
Combination Product
Lead sponsor
Ascendis Pharma Bone Diseases A/S
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 30, 2026, 9:21 PM EDT
Recruiting No phase listed Observational

A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT07677254
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 115 Years · Male only
Enrollment
17,111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 9:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pain in Fibrous Dysplasia

NCT04125862
View directory record Official record
Conditions
Fibrous Dysplasia/McCune-Albright Syndrome
Interventions
MRI-based Neuroimaging, Non-contrast MRI, 18F-FDG-PET/CT, 18F-NaF-PET/CT
Diagnostic Test
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 9:21 PM EDT
Completed Phase 1 Interventional

Axillary Reverse Mapping for Invasive Carcinoma of the Breast

NCT00645541
View directory record Official record
Conditions
Breast Cancer
Interventions
Axillary Reverse Mapping
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 30, 2026, 9:21 PM EDT
Completed Early Phase 1 Interventional

Feasibility of Near-infrared Spectroscopy to Measure Cortical Pain Pathway (Brain) Activation During Dry Needling

NCT04170803
View directory record Official record
Conditions
Shoulder Pain, Chronic Pain, Musculoskeletal Injury
Interventions
Dry Needling, Sham Dry Needling
Device · Other
Lead sponsor
Army-Baylor University Doctoral Program in Physical Therapy
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 30, 2026, 9:21 PM EDT
Completed No phase listed Observational

Evaluating the Response of the Immune System of People With Long COVID (Post SARS-CoV-2)

NCT05131594
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Huntington Memorial Hospital
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 9:21 PM EDT
Completed Phase 2 Interventional Results available

Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients

NCT02420223
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Propranolol
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 30, 2026, 9:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nutrigenomics: Personalizing Weight Loss for Obese Veterans

NCT01859403
View directory record Official record
Conditions
Obesity
Interventions
Personalized Genomics, Usual Care
Genetic
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 30, 2026, 9:21 PM EDT
Completed Not applicable Interventional

Stress and Immunity Breast Cancer Project

NCT03578627
View directory record Official record
Conditions
Breast Cancer Stage II, Breast Cancer Stage III
Interventions
BioBehavioral Intervention
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 30, 2026, 9:21 PM EDT
Completed Phase 2 Interventional Results available

Everolimus in Treating Patients With Recurrent Low-Grade Glioma

NCT00823459
View directory record Official record
Conditions
Adult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Subependymal Giant Cell Astrocytoma, Recurrent Adult Brain Neoplasm
Interventions
Everolimus, Archival Tissue Analysis
Drug · Other
Lead sponsor
Susan Chang
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 30, 2026, 9:21 PM EDT
Active, not recruiting Not applicable Interventional

TEAMS R34 #3: Team-Based Implementation Strategy for Pediatric Depression Screening

NCT06527196
View directory record Official record
Conditions
Depression, Children
Interventions
Team-Enhanced Condition, Standard Condition
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 30, 2026, 9:21 PM EDT
Enrolling by invitation Phase 2 Interventional

Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

NCT06751602
View directory record Official record
Conditions
Rejection Chronic Renal
Interventions
Belumosudil 200 mg QD, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 30, 2026, 9:21 PM EDT
Completed Phase 1 Interventional

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

NCT04959981
View directory record Official record
Conditions
Advanced Non-squamous Non-small-cell Lung Cancer
Interventions
ERAS-007, ERAS-601, Osimertinib, Sotorasib
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Duarte, California • Orange, California • Santa Monica, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 30, 2026, 9:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

NCT07206056
View directory record Official record
Conditions
Progressive Metastatic Castrate Resistant Prostate Cancer
Interventions
Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD, JSB462 Dose 1 QD, JSB462 Dose 2 QD, JSB462 QD, Standard of Care (SoC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 9:21 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy

NCT04191928
View directory record Official record
Conditions
Pancreas Cancer, DVT, Pulmonary Embolism
Interventions
Apixaban
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 30, 2026, 9:21 PM EDT
Completed Not applicable Interventional

Impact of a Prehospital Sepsis Protocol on Timely Antibiotic Administration and Subsequent Adverse Events

NCT05502107
View directory record Official record
Conditions
Sepsis
Interventions
PRESS Intervention
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia • Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 30, 2026, 9:21 PM EDT
Terminated Phase 1 Interventional

MT2004-30: Tomotherapy for Solid Tumors

NCT00623077
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma, Sarcoma
Interventions
filgrastim, busulfan, etoposide, ifosfamide, melphalan, thiotepa, stem cell transplantation, tomotherapy, total marrow irradiation, Mesna, Whole lung radiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 30, 2026, 9:21 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Noninvasive Markers of Functional Nausea in Children

NCT03593811
View directory record Official record
Conditions
Nausea
Interventions
Questionnaires, 4 channel electrogastrogram (EGG), 36 channel high resolution electrogastrogram (HR-EGG), Magnetogastrogram (MGG), Electrocardiogram (EKG), Ondansetron, Cyproheptadine Oral Tablet
Diagnostic Test · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
8 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 9:21 PM EDT
Recruiting Phase 1 Interventional

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

NCT07075120
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Ipilimumab and Nivolumab, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 30, 2026, 9:21 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Utilization of a Web-Based Application to Improve Patient Health Literacy and Reduce Clinic Visit Times in Holmium Laser Enucleation of the Prostate (HoLEP) Procedures and Kidney Stone Surgery

NCT07580391
View directory record Official record
Conditions
Kidney Stone, Benign Prostatic Hyperplasia
Interventions
WellPrept, Standard Care
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 30, 2026, 9:21 PM EDT
Completed Phase 2 Interventional Results available

Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.

NCT03427866
View directory record Official record
Conditions
Myelofibrosis
Interventions
Ruxolitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
5
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 30, 2026, 9:21 PM EDT